Loading…

Engineering CAR T cells for enhanced efficacy and safety

Despite its success in treating hematologic malignancies, chimeric antigen receptor (CAR) T cell therapy faces two major challenges which hinder its broader applications: the limited effectiveness against solid tumors and the nonspecific toxicities. To address these concerns, researchers have used s...

Full description

Saved in:
Bibliographic Details
Published in:APL Bioengineering 2022-03, Vol.6 (1), p.011502-011502-14
Main Authors: Wu, Yiqian, Huang, Ziliang, Harrison, Reed, Liu, Longwei, Zhu, Linshan, Situ, Yinglin, Wang, Yingxiao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite its success in treating hematologic malignancies, chimeric antigen receptor (CAR) T cell therapy faces two major challenges which hinder its broader applications: the limited effectiveness against solid tumors and the nonspecific toxicities. To address these concerns, researchers have used synthetic biology approaches to develop optimization strategies. In this review, we discuss recent improvements on the CAR and other non-CAR molecules aimed to enhance CAR T cell efficacy and safety. We also highlight the development of different types of inducible CAR T cells that can be controlled by environmental cues and/or external stimuli. These advancements are bringing CAR T therapy one step closer to safer and wider applications, especially for solid tumors.
ISSN:2473-2877
2473-2877
DOI:10.1063/5.0073746